TriSalus launches warrant exchange offer at 0.3 shares per warrant; seeks to reduce dilution

TriSalus Life Sciences, Inc.

Offering up to 4,264,532 common shares for up to 14.2M warrants (0.30 per warrant).
34.8% of Public Warrants pre-committed; needs ~15.3% more to meet majority threshold.
Consent solicitation seeks amendment allowing forced conversion at 0.27 shares (10% discount).
Expiration date: June 25, 2024; Oppenheimer & Co. is dealer manager.
Company aims to simplify capital structure and reduce future dilutive impact of warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.